Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 2:19:9459-9486.
doi: 10.2147/IJN.S466396. eCollection 2024.

Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects

Yueyao Jiang #  1 , Chengran Wang #  2 , Chuancheng Zu #  3 , Xin'ao Rong  2 , Qian Yu  1 , Jinlan Jiang  2
Affiliations
Review

Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects

Yueyao Jiang et al. Int J Nanomedicine. .

Abstract

Given the global prevalence of prostate cancer in men, it is crucial to explore more effective treatment strategies. Recently, immunotherapy has emerged as a promising cancer treatment due to its unique mechanism of action and potential long-term effectiveness. However, its limited efficacy in prostate cancer has prompted renewed interest in developing strategies to improve immunotherapy outcomes. Nanomedicine offers a novel perspective on cancer treatment with its unique size effects and surface properties. By employing targeted delivery, controlled release, and enhanced immunogenicity, nanoparticles can be synergized with nanomedicine platforms to amplify the effectiveness of immunotherapy in treating prostate cancer. Simultaneously, nanotechnology can address the limitations of immunotherapy and the challenges of immune escape and tumor microenvironment regulation. Additionally, the synergistic effects of combining nanomedicine with other therapies offer promising clinical outcomes. Innovative applications of nanomedicine include smart nanocarriers, stimulus-responsive systems, and precision medicine approaches to overcome translational obstacles in prostate cancer immunotherapy. This review highlights the transformative potential of nanomedicine in enhancing prostate cancer immunotherapy and emphasizes the need for interdisciplinary collaboration to drive research and clinical applications forward.

Keywords: TME; immunotherapy; nanomedicine; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

None
Graphical abstract
Figure 1
Figure 1
Optimization strategies of nanoparticles for the treatment of prostate cancer.
Figure 2
Figure 2
Nanomedicines can be utilized to boost tumor immunogenicity in combination with CDT, SDT, PDT, and RT.
Figure 3
Figure 3
(A). Cancer vaccine platforms and interactions in the immune system; (B). PD-1/PD-L1 are involved in immune checkpoint blockade (ICB) therapy; (C).CAR-T cell immunotherapy process.
Figure 4
Figure 4
Using databases and AI to design nanomaterials for immune response and immunotherapy.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer j Clin. 2023;73(1):17–48. doi:10.3322/caac.21763 - DOI - PubMed
    1. Chowdhury S, Bjartell A, Lumen N, et al. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: the Prostate Cancer Registry. Targ Oncol. 2020;15(3):301–315. doi:10.1007/s11523-020-00720-2 - DOI - PMC - PubMed
    1. Gillessen S, Attard G, Beer TM, et al. Management of Patients with Advanced Prostate Cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. Europ urol. 2020;77(4):508–547. doi:10.1016/j.eururo.2020.01.012 - DOI - PubMed
    1. Nuhn P, De Bono JS, Fizazi K, et al. Update on Systemic Prostate Cancer Therapies: management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Europ urol. 2019;75(1):88–99. doi:10.1016/j.eururo.2018.03.028 - DOI - PubMed
    1. Cancer Immunotherapy.